Clinical trial registry: A randomized, placebo-controlled pilot study in Huntington's disease: citalopram to enhance cognition in HD (CIT-HD). http://clinicaltrials.gov/show/NCT00271596.
Results of the citalopram to enhance cognition in Huntington disease trial
Article first published online: 27 DEC 2013
© 2013 International Parkinson and Movement Disorder Society
Volume 29, Issue 3, pages 401–405, March 2014
How to Cite
Beglinger, L. J., Adams, W. H., Langbehn, D., Fiedorowicz, J. G., Jorge, R., Biglan, K., Caviness, J., Olson, B., Robinson, R. G., Kieburtz, K. and Paulsen, J. S. (2014), Results of the citalopram to enhance cognition in Huntington disease trial. Mov. Disord., 29: 401–405. doi: 10.1002/mds.25750
Funding agencies: National Institutes of Health (NS055733-01 to L.J.B.); CHDI Foundation; University of Iowa Center for Clinical and Translational Research; Huntington Disease Society of America (to J.S.P.) for the University of Iowa HD Center of Excellence; National HD Research Roster.
Relevant conflicts of interest/financial disclosures: Nothing to report.
Full financial disclosures and author roles may be found in the online version of this article.
- Issue published online: 17 MAR 2014
- Article first published online: 27 DEC 2013
- Manuscript Accepted: 21 OCT 2013
- Manuscript Revised: 16 OCT 2013
- Manuscript Received: 22 MAR 2013
- Huntington disease;
- neuropsychological assessment;
- cognitive disorders/dementia;
- clinical trial
The objective of this study was to evaluate citalopram for executive functioning in Huntington's disease (HD).
The study was randomized, double-blind, and placebo-controlled. Thirty-three adults with HD, cognitive complaints, and no depression (Hamilton Depression [HAM-D] rating scale ≤12) were administered citalopram 20 mg or placebo (7 visits, 20 weeks), with practice and placebo run-ins. The primary outcome was change in executive functioning.
The intent to treat analysis was controlled for practice effects, comparing visits 1 and 2 to visits 5 and 6 for citalopram versus placebo. There were no significant benefits on the executive function composite (treatment-placebo mean difference −0.167; 95% confidence interval [CI], −0.361 to 0.028; P = .092). Citalopram participants showed improved clinician-rated depression symptoms on the HAM-D (t = −2.02; P = 0.05). There were no group differences on motor ratings, self-reported executive functions, psychiatric symptoms, or functional status.
There was no evidence that short-term treatment with citalopram improved executive functions in HD. Despite excluding patients with active depression, participants on citalopram showed improved mood, raising the possibility of efficacy for subsyndromal depression in HD. © 2013 International Parkinson and Movement Disorder Society